You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A nanoparticle delivery system for CRISPR Cas based therapeutics

    SBC: ATGC Inc.            Topic: NCATS

    Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Fc folate Conjugate for the Treatment of Triple Negative Breast Cancer

    SBC: NeuLink Inc.            Topic: 100

    Abstract According to the American Cancer Society in women in the U S will develop breast cancer at some point in their life and of these women will have triple negative breast cancer TNBC an aggressive subtype of breast cancer that lacks the three receptors ER PR HER that current drug treatment targets tamoxifen Herceptin Because of its aggressive nature and lack of effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Self expanding hydrogel for pelvic brachytherapy a novel method for vaginal packing and customized radiation therapy

    SBC: BrachyFoam, LLC            Topic: 102

    This proposal aims to develop a polymer hydrogel strategy that can be used to improve the clinical care of patients receiving brachytherapy for gynecological cancers The biocompatible hydrogel will form in situ after being injected into the vaginal space and later removed by instillation of water to soften the hydrogel for easy extraction This Phase I proposal focuses on optimizing the polymer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic disruption of Connexin mediated microtubule regulation to target glioblastoma cancer stem cells

    SBC: Acomhal Research, Inc.            Topic: 100

    Project Summary Glioblastoma GBM is one of the most lethal incurable human diseases Even with aggressive therapies including surgical resection followed by radiotherapy and chemotherapy using temozolomide TMZ the median survival for GBM patients is only months In fact GBM cancer cells are highly infiltrative and comprise a sub population of glioma stem cells GSCs with tumorigenic pro ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. GRIM for head and neck cancer therapy

    SBC: GLYCOMANTRA INC            Topic: 102

    Project Summary Many clinical and preclinical studies demonstrated that interferons IFNs exert a superior anti tumor effect when combined with retinoids a class of vitamin A metabolites We identified a novel tumor suppressor Gene associated with Retinoid IFN induced Mortality GRIM by a genome wide knockdown strategy In our recent publication in the PNAS we have shown that GRIM g ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections

    SBC: TSRL, INC.            Topic: NIAID

    Abstract In the United Statesskin and soft tissue infectionsSSTIsare one of the most common indications for antibiotic treatmentrepresentingof hospital admissions andmillion doctor visits a yearSSTIs range from selflimiting furuncles and cellulitis to life threatening sepsis and tissue necrosisRecent studies suggest more thanof all SSTIs were caused by staphylococcal or streptococcal speciesin par ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor

    SBC: CAYMAN CHEMICAL COMPANY, INCORPORATED            Topic: NIA

    PROJECT SUMMARY Millions of Americans are suffering from the devastation of cognition decline and other neurological dysfunctions due to one of the neurodegenerative diseases of tauopathy Some of the prominent tauopathies include Alzheimer s disease Pick s disease traumatic brain injury and chronic encephalopathy There is no cure for any of the tauopathies and the actual cause or exogenous r ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government